Pressure BioSciences, Inc. to Present at the 2017 Disruptive Growth Company Showcase in New York City on September 27, 2017
SOUTH EASTON, MA / ACCESSWIRE / September 25, 2017 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"), a leader in the development and sale of broadly enabling, pressure cycling technology ("PCT")-based sample preparation solutions to the worldwide life sciences industry, today announced that Mr. Richard T. Schumacher, President and CEO, will present a corporate overview at the 2017 Disruptive Growth Company Showcase. The conference is being held at the Grand Hyatt Hotel in New York City.
Mr. Schumacher's presentation is scheduled for 10:30am ET on Wednesday, September 27, 2017. Following the Company's presentation, Mr. Schumacher will be available to participate in one-on-one meetings with investors and other stakeholders in the Company.
The Disruptive Growth Company Showcase is being co-hosted by SeeThruEquity, a leading provider of high quality research on undervalued smallcap and microcap equities, and RHK Capital, a boutique investment banking firm specializing in small to medium-sized transactions. If you are an investor and would like to attend the conference, information is available at www.disruptnyc.com.
The Company's presentation will be webcast live at: http://www.investorcalendar.com/event/20351. The webcast replay will remain available for 90 days on the Pressure BioSciences website.
News Compliments of ACCESSWIRE.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or "PCT") hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug development and design, bio-therapeutics characterization, soil & plant biology, forensics, and counter-bioterror applications. Our secondary focus is in the use of our patented, scalable, high efficiency homogenization platform (i.e., Ultra Shear Technology, or "UST") to create nanoemulsions of otherwise immiscible fluids, such as oils and water. Because they have been shown to offer high thermodynamic stability, increased bio-availability, rapid dissolution and uptake, and decreased pathogen levels, nanoemulsions have recently generated great interest in the pharmaceutical, cosmetics, nutraceuticals, and food preservation and safety areas.
For more information about PBI and this press release, please click on the following link:
Please visit us on Facebook, LinkedIn, and Twitter.
Richard T. Schumacher, President & CEO - (T) 508-230-1828
Jeffrey N. Peterson, Chairman - (T) 650 812-8121
SOURCE: Pressure BioSciences, Inc.
Released September 25, 2017